A Review About Pembrolizumab in First-Line Treatment of Advanced NSCLC: Focus on KEYNOTE Studies

Overview of attention for article published in Cancer Management and Research, July 2020

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (75th percentile)
High Attention Score compared to outputs of the same age and source (94th percentile)

So far, Altmetric has seen 2 news stories from 1 outlets.

By M. Marin NASDAQ:AEMD READ THE FULL AEMD RESEARCH REPORT Next step: AEMD will submit cumulative data to sites interested in…

By M. Marin NASDAQ:AEMD Moving forward towards oncology clinical studies in India